Karen joined Advent in 2020 and brings 30 years of industry experience in strategy and collaborations for pharmaceutical and biotechnology companies in the United States, Europe and China, including strategic collaborations and mergers & acquisitions.
Karen spent the first 20 years of her career with Bristol-Myers Squibb. She has since served as Chief Business Officer with PsiOxus Therapeutics and WindMil Therapeutics as well as Advent Portfolio companies Artax Biopharma and Aleta Biotherapeutics. Karen serves on the board of directors of PaxMedica, a clinical stage autism company.
Karen received her MBA from Columbia University and Bachelor of Science in Industrial Engineering from Lehigh University where she currently serves on the P.C Rossin School of Engineering Advisory Board.
We use our own and third party cookies that are essential to make our website work. We also use other cookies for analytics on site usage to help us improve our site and give you an easy and personalised experience. You can 'Accept All' other cookies or customise your preferences to reject or permit specific cookies by visiting "Cookie Consent" and selecting "Cookie Settings" in the pop-up at the bottom of the window.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.